07 The matter of the debate: this house believes that we should (follow the EMA guidelines and) avoid using DOACs in APS and SLE/APS (Against)

Learning ObjectivesAt the end of this presentation participants will be able to:. Explain why DOACs should not be used in patients with thrombotic APS .Discuss why more studies are needed to assess whether this assumption is valid for high-risk patients (i.e.triple positive) only .Discuss why more studies are needed to assess whether DOACs could be used in low risk (double or single positive) patients with VTE 07